Rheonix, Ithaca, NY, has received FDA emergency use authorization for its Covid-19 MDx assay, a fully automated test that enables detection of SARS-CoV-2, the virus that causes covid-19, directly from respiratory samples. The test is designed to operate on the Rheonix Encompass MDx workstation and will facilitate same-day test results for small- and medium-throughput laboratories.
The Rheonix Covid-19 MDx assay is a sample-to-answer test that requires no technician involvement after loading the samples onto the workstation. The system enables cost-effective on-site testing at distributed locations, allowing for more rapid decisions regarding isolation and treatment of infected patients. Rheonix has begun shipment of the workstation and test kits to high-need local and regional hospital laboratories to enable them to begin testing immediately.
“Rapid diagnosis is critical in efforts to control the SARS-CoV-2 virus,” says Richard Montagna, PhD, FACB, senior vice president for scientific and clinical affairs at Rheonix. “We at Rheonix are grateful to the people on the front lines fighting the spread of the covid-19 illness and are proud to be able to support them with a rapid, accurate, and automated tool to assist in their efforts.”
For more information, visit Rheonix.